Skip to main content

Advertisement

SpringerLink
Log in

Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment

  • Review
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Interstitial pneumonitis has been described infrequently following administration of docetaxel, used alone or in combination with other chemotherapeutic agents or concurrent irradiation, for non-small-cell lung cancer (NSCLC). This toxicity is of special relevance in NSCLC, as clinical severity and differential diagnosis may be especially challenging. It seems to be due to type I and type IV hypersensitivity reactions to the drug. Clinical and radiographic features are nonspecific and diagnosis is made by exclusion. The rate of grade III–IV docetaxel-induced pneumonitis, ranging from 7 to 47%, depends on several factors, including total dose, chemotherapy schedule and especially concomitant docetaxel treatment with gemcitabine and radiotherapy. Although the usual outcome is cure, it sometimes eventually progresses to pulmonary fibrosis despite steroid treatment. This toxicity must be taken into account when planning treatment strategies for NSCLC in order to reduce its rate and to achieve prompt diagnosis and treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stover DE, Kaner JR (2005) Pulmonary toxicity. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology, 7th Edn. Lippincott Williams and Wilkins, Philadelphia, pp 2535–2545

    Google Scholar 

  2. (2006) Interstitial pneumonia in Taxotere. In: Micromedex. Healthcare series. Available at: http://www.micromedex.com

  3. (2006) Taxane-induced pulmonary toxicity. UptoDate version 14.3. Available at: http://www.uptodate.com

  4. Karakan O, Eyuboglu FO, Akcay S, Ozylkan O (2004) Acute interstitial pneumopathy associated with docetaxel hypersensitivity. Onkologie 27:563–565

    Article  CAS  Google Scholar 

  5. Karasawa K, Katsui K, Seki K et al (2003) Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer. Breast Cancer 10:268–274

    Article  PubMed  Google Scholar 

  6. Behrens RJ, Gulley JL, Dahut WL (2003) Pulmonary toxicity during prostate cancer treatment with docetaxel and thalidomide. Am J Ther 10:228–232

    Article  PubMed  Google Scholar 

  7. Dunsford ML, Mead GM, Bateman AC et al (1999) Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 10:943–947

    Article  PubMed  CAS  Google Scholar 

  8. Read WL, Mortimer JE, Picus J (2002) Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94:847–853

    Article  PubMed  Google Scholar 

  9. Etienne B, Perol M, Nesme P et al (1998) Acute diffuse interstitial pneumopathy following docetaxel. A propos of 2 cases. Rev Mal Respir 15:199–203

    PubMed  CAS  Google Scholar 

  10. Wang GS, Yang KY, Perng RP (2001) Life-threatening hypersensitivity pneumonitis induced by docetaxel. Br J Cancer 85:1247–1250

    Article  PubMed  CAS  Google Scholar 

  11. Chen YM, Shih JF, Lee CS et al (2003) Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Lung Cancer 39:209–214

    Article  PubMed  Google Scholar 

  12. Hainsworth JD, Burris HA, Greco FA (2001) Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer. Semin Oncol 28:21–25

    Article  PubMed  CAS  Google Scholar 

  13. Chen YM, Perg RP, Lin WC et al (2002) Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 25:509–512

    Article  PubMed  Google Scholar 

  14. Kouroussis C, Mavroudis D, Kakolyris S et al (2004) High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. Lung Cancer 44:363–368

    Article  PubMed  Google Scholar 

  15. Fernández Y, Esteban E, Villanueva J et al (2006) Prospective randomised phase II study of gemcitabine and vinorelbine versus gemcitabine and docetaxel combination in patients with previously untreated advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 671:17052

    Google Scholar 

  16. McNeill G, Kalmadi S, Davis M et al (2006) Phase II trial of weekly docetaxel and gemcitabine as first line therapy for patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 673:17076

    Google Scholar 

  17. Popa IE, Stewart K, Smith FP, Rizvi NA (2002) A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive advanced non-small cell lung carcinoma. Cancer 95:1714–1719

    Article  PubMed  CAS  Google Scholar 

  18. Onishi H, Kuriyama K, Yamaguchi M et al (2003) Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 40:79–84

    Article  PubMed  Google Scholar 

  19. Vergnenegre A, Daniel C, Lena H et al (2005) Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small cell lung cancer. Lung Cancer 47:395–404

    Article  PubMed  CAS  Google Scholar 

  20. Jang TW, Park JP, Kim HK et al (2004) Concurrent docetaxel-cisplatin and thoracic radiotherapy for locally advanced non-small cell lung cancer. Tuberc Respir Dis 57:257–264

    Google Scholar 

  21. Sakai H, Yoneda S, Kobayashi K et al (2004) Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III non-small cell lung cancer. Lung Cancer 43:195–201

    Article  PubMed  Google Scholar 

  22. Bedano PM, Neubauer M, Ansari R et al (2006) Phase III study of cisplatin plus etoposide with concurrent chest radiation followed by docetaxel vs. observation in patients with stage III non-small cell lung cancer: an interim toxicity analysis of consolidation therapy. Proc Am Soc Clin Oncol 374:7043

    Google Scholar 

  23. Gandara DR, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage III non-small-cell lung cancer: Phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004–2010

    Article  PubMed  CAS  Google Scholar 

  24. Sekine I, Nokihara H, Sumi M et al (2006) Docetaxel consolidation therapy following cisplatin, vinorelbine and concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Thorac Oncol 8:810–815

    Article  Google Scholar 

  25. Moon C, Verschraegen CF, Bevers M et al (2000) Use of docetaxel in patients with paclitaxel hypersensitivity. Anticancer Drugs 11:565

    Article  PubMed  CAS  Google Scholar 

  26. Denman JP, Gilbar PJ, Abdi EA (2002) Hypersensitivity reaction to docetaxel after a previous hypersensitivity reaction to paclitaxel. J Clin Oncol 20:2760

    PubMed  Google Scholar 

  27. Chen YM, Shif JF, Perng RP et al (2006) A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 129:1031–1038

    Article  PubMed  CAS  Google Scholar 

  28. (2006) Radiation-induced lung injury. UptoDate, version 14.3. Available at http://www.uptodate.com

  29. Villanueva N, Esteban E, Muñiz I et al (2006) Weekly 70 Gy thoracic radiotherapy concurrent with docetaxel or paclitaxel alter induction chemotherapy of patients with locally advanced non-small cell lung cancer. Prospective study of tolerance and efficacy. Oncología 29:30–36

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital Meixoeiro. Complejo Hospitalario y Universitario de Vigo, ES-36200, Vigo, Spain

    C. Grande, M. J. Villanueva, G. Huidobro & J. Casal

Authors
  1. C. Grande
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. J. Villanueva
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Huidobro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Casal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grande, C., Villanueva, M.J., Huidobro, G. et al. Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol 9, 578–581 (2007). https://doi.org/10.1007/s12094-007-0106-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-007-0106-4

Key words

Search

Navigation